Active Ingredient History
Mexiletine is a non-selective voltage-gated sodium channel blocker which belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat heart arrhythmias. Mexiletine is also used to treat refractory pain and muscle stiffness resulting in myotonic dystrophy or myotonia congenita. Mexiletine was approved for commercial use in 1985 under the brand name Mexitil, but most marketing efforts have since been discontinued. There has been a continued effort to identify other therapeutic use cases and a number of clinical trials have been conducted including ALS and chronic pain from amputation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Arrhythmias, Cardiac (approved 1985)
Muscle Cramp (approved 1985)
Amputation, Surgical (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 4)
Arrhythmias, Cardiac (Phase 3)
Blepharospasm (Phase 2)
Cardiotoxicity (Phase 1)
Cardiovascular Diseases (Phase 3)
Charcot-Marie-Tooth Disease (Phase 2)
Chronic Pain (Phase 2)
Death, Sudden, Cardiac (Phase 3)
Diabetic Neuropathies (Phase 3)
Dystonia (Phase 2)
Heart Arrest (Phase 3)
Heart Diseases (Phase 3)
HIV Infections (Phase 2)
Irritable Bowel Syndrome (Phase 1)
Myocardial Infarction (Phase 3)
Myotonia (Phase 3)
Myotonia Congenita (Phase 3)
Myotonic Disorders (Phase 3)
Myotonic Dystrophy (Phase 3)
Pain (Phase 3)
Paresthesia (Phase 3)
Peripheral Nervous System Diseases (Phase 2)
Pharmacokinetics (Phase 1)
Polyradiculoneuropathy (Phase 4)
Spasm (Phase 2)
Tachycardia (Phase 4)
Tachycardia, Ventricular (Phase 3)
Ventricular Fibrillation (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue